Richard Nolan Townsend Sells 5,000 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $977,629.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, September 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $10.65, for a total transaction of $53,250.00.
• On Monday, August 12th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $11.53, for a total transaction of $57,650.00.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $9.15 on Thursday. The firm has a market cap of $301.45 million and a PE ratio of -0.41. The firm has a fifty day moving average of $10.31 and a 200 day moving average of $12.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. Lexeo Therapeutics, Inc. has a one year low of $7.86 and a one year high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting the consensus estimate of ($0.64). As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in shares of Lexeo Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after buying an additional 3,483 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after buying an additional 3,627 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Lexeo Therapeutics during the first quarter worth $75,000. American International Group Inc. purchased a new stake in shares of Lexeo Therapeutics during the first quarter worth $79,000. Finally, Vanguard Group Inc. grew its holdings in shares of Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after buying an additional 65,573 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LXEO. HC Wainwright cut their target price on shares of Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, August 14th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $22.14.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.